FDA approved Belbuca (buprenorphine) Buccal Film for Severe Persistent PainFDA approved Belbuca film for severe pain that needs daily opioid treatment.

FDA From the archive Source published October 23, 2015 Summary added June 25, 2026 DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider Belbuca for severe persistent pain only when alternative options are inadequate; initiate at lowest dose and titrate cautiously.

The FDA has approved Belbuca (buprenorphine) buccal film for the management of severe and persistent pain that requires an opioid analgesic and cannot be adequately treated with alternative options, including immediate-release opioids. Belbuca is a partial opioid agonist administered via buccal film, designed for around-the-clock use rather than as-needed (prn) analgesia. The approval comes with a boxed warning highlighting risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration. Clinicians are advised to reserve Belbuca for patients in whom alternative treatments are ineffective, not tolerated, or otherwise inadequate. The drug is not indicated for as-needed use. Dosing must be individualized, starting at 75 mcg for non-opioid-tolerant patients, with specific conversion guidelines for those switching from other opioids.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Buprenorphine is a partial opioid agonist. It binds to mu-opioid receptors in the central nervous system, producing analgesia.

Indication & Patient Population

Belbuca is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. It is not indicated as an as-needed (prn) analgesic.

Dosing & Administration

Belbuca should be prescribed only by healthcare professionals knowledgeable about extended-release/long-acting opioids. Use the lowest effective dosage for the shortest duration. For non-opioid-tolerant patients: initiate with 75 mcg once daily or every 12 hours for at least 4 days before increasing to 150 mcg every 12 hours. For conversion from other opioids: taper current daily opioid dose to 30 mg oral morphine sulfate equivalents (MSE) or less prior to starting. For patients taking less than 30 mg MSE: start 75 mcg once daily or every 12 hours. For 30-89 mg MSE: start 150 mcg every 12 hours. For 90-160 mg MSE: start 300 mcg every 12 hours. For >160 mg MSE: consider alternate analgesic. Doses of 600 mcg, 750 mcg, and 900 mcg are only for use following titration from lower doses. For severe hepatic impairment or oral mucositis: reduce starting and incremental dose by half. Apply to buccal mucosa once daily or every 12 hours.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Risks of addiction, abuse, misuse, overdose, and death. Respiratory depression can occur at any time, especially during initiation and dose increases. Discuss overdose reversal agents with patients/caregivers. Do not rapidly reduce or abruptly discontinue in physically-dependent patients. Not for as-needed use.

Place in Therapy

Belbuca is reserved for patients with severe persistent pain requiring an opioid when alternative treatments are ineffective, not tolerated, or inadequate. It is a long-acting option for around-the-clock use, not for prn analgesia.

The FDA has approved a new drug called Belbuca (buprenorphine) for the management of severe, persistent pain that requires daily, around-the-clock treatment with an opioid. Belbuca is a buccal film that dissolves inside the cheek. It is a partial opioid agonist, which means it works on the same brain receptors as other opioids but with a lower risk of respiratory depression at typical doses.

Belbuca is intended for patients whose pain cannot be adequately controlled with other treatments, including immediate-release opioids. It is not for use as needed for pain. The drug comes with a boxed warning about the risks of addiction, abuse, misuse, overdose, and death, which can happen at any dose or duration of use.

The approval means that doctors now have another option for patients with severe chronic pain who need continuous opioid therapy. However, because of the risks, Belbuca should be reserved for patients who have not found relief with other treatments. Dosing must be carefully individualized, starting at a low dose for those not already taking opioids.

If you or a loved one are struggling with severe pain, talk to your doctor about whether Belbuca might be an option. Your doctor can help weigh the benefits and risks based on your specific health situation. Remember, this medication is only for severe, persistent pain and requires close medical supervision.

What this means for you:

Belbuca is a new daily opioid film for severe pain, not for occasional use. Talk to your doctor.

Study Details

Study typeFda approval

PublishedOct 2015

View Original Abstract ↓

1 INDICATIONS AND USAGE BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. BELBUCA buccal film contains buprenorphine, a partial opioid agonist. BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including BELBUCA, for use in patients for whom alternative treatment are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) BELBUCA is not indicated as an as-needed (prn) analgesic. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including BELBUCA, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. BELBUCA is not indicated as an as-needed (prn) analgesic.

FDA approved Belbuca (buprenorphine) Buccal Film for Severe Persistent PainFDA approved Belbuca film for severe pain that needs daily opioid treatment.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

FDA approved Belbuca (buprenorphine) Buccal Film for Severe Persistent PainFDA approved Belbuca film for severe pain that needs daily opioid treatment.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties